ArticleBlood vessels, thrombosis & hemostasis2026
Interindividual variability in platelet aggregation among aspirin-treated patients: a large retrospective analysis.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interindividual variability in response to aspirin remains a major challenge in antiplatelet therapy. Identification of patients with high platelet reactivity (HPR) and optimal or low platelet reactivity remains challenging and may be influenced by both biological and methodological factors, including interlaboratory variability. We report results of a large cohort of aspirin-treated patients to assess the gold standard light transmission aggregometry (LTA). We retrospectively analyzed 3065 patients treated with aspirin (ASA; 75-150 mg/d) who sequentially underwent LTA assessment using multiple agonists (adenosine diphosphate [ADP] 2μM, collagen 2 μg/mL, arachidonic acid [AA] 0.75mM, and epinephrine 10μM). Patients were stratified according to AA-induced platelet aggregation using a 16% cutoff (third quartile). Patients with AA >16% showed significantly higher platelet aggregation across all agonists (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.